TOP TEN perturbations for 1552315_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552315_at
Selected probe(set): 1552316_a_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552315_at (1552316_a_at) across 6672 perturbations tested by GENEVESTIGATOR:

B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)

Relative Expression (log2-ratio):-4.648816
Number of Samples:4 / 4
Experimental B-CLL study 11 (rolipram)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:---
Control rolipram study 4 (normal T-cell; 20uM)
MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:---

rheumatoid arthritis study 31 / TNF-ɑ study 20

Relative Expression (log2-ratio):4.184637
Number of Samples:4 / 3
Experimental rheumatoid arthritis study 31
Monocyte samples isolated from patients with rheumatoid arthritis (RA). Monocytes from whole blood were depleted from granulocytes by CD15 MACS beads, and afterwards they were sorted from remaining peripheral blood leukocytes by CD14 labeling. Patients fulfilled the revised American College of Rheumatology criteria (ACR) for RA.
Control TNF-ɑ study 20
Monocyte samples isolated from healthy donors and stimulated in vitro by 100 ng/ml TNFα in whole blood for 1.5 hour. Following stimulation, monocytes were depleted from granulocytes using CD15 MACS beads, and afterwards they were sorted from remaining peripheral blood leukocytes by CD14 labeling.

TNF-ɑ study 20 / normal monocyte sample

Relative Expression (log2-ratio):-4.116438
Number of Samples:3 / 7
Experimental TNF-ɑ study 20
Monocyte samples isolated from healthy donors and stimulated in vitro by 100 ng/ml TNFα in whole blood for 1.5 hour. Following stimulation, monocytes were depleted from granulocytes using CD15 MACS beads, and afterwards they were sorted from remaining peripheral blood leukocytes by CD14 labeling.
Control normal monocyte sample
Monocyte samples isolated from healthy subjects. Peripheral blood monocytes were isolated immediately after drawing blood by depletion from granulocytes using CD15 MACS beads, and afterwards they were sorted from remaining peripheral blood leukocyte by CD14 labeling.

B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample

Relative Expression (log2-ratio):-4.0174417
Number of Samples:4 / 4
Experimental B-CLL study 11 (DMSO)
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l.
Control vehicle (DMSO) treated normal T-cell sample
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours.

TNF-ɑ study 20 / unstimulated monocyte sample

Relative Expression (log2-ratio):-3.7466946
Number of Samples:3 / 11
Experimental TNF-ɑ study 20
Monocyte samples isolated from healthy donors and stimulated in vitro by 100 ng/ml TNFα in whole blood for 1.5 hour. Following stimulation, monocytes were depleted from granulocytes using CD15 MACS beads, and afterwards they were sorted from remaining peripheral blood leukocytes by CD14 labeling.
Control unstimulated monocyte sample
Monocyte samples isolated from healthy donors and incubated in whole blood for 1.5 hour without any stimulation. Following incubation, monocytes were depleted from granulocytes using CD15 MACS beads, and afterwards they were sorted from remaining peripheral blood leukocytes by CD14 labeling.

IL-4; GM-CSF study 1 (early) / untreated monocyte sample

Relative Expression (log2-ratio):-3.702776
Number of Samples:6 / 12
Experimental IL-4; GM-CSF study 1 (early)
Monocytes, cultured with vehicle (DMSO/ethanol) and 500 U/ml IL-4 and 800 U/ml GM-CSF for 6 hours.
Control untreated monocyte sample
Freshly isolated human monocytes from healthy donors.

atopic dermatitis study 21 (lesional; whole skin) / normal skin tissue

Relative Expression (log2-ratio):-3.5814772
Number of Samples:5 / 6
Experimental atopic dermatitis study 21 (lesional; whole skin)
Lesional full thickness skin samples isolated from patient with moderate-to-severe atopic dermatitis by laser capture microdissection. Patients' cohort characteristics: 3 males and 2 females; age 27-59 years (mean age: 39.4 years); SCORing of Atopic Dermatitis index (SCORAD) ranging from 45-65; total IgE: 14-1821 kU/l; eosinophilic count: 1.4-11.8 %.
Control normal skin tissue
Full thickness skin samples isolated from healthy subjects by laser capture microdissection.

B-CLL study 9 (CD19+; CD5+; untreated) / untreated normal B-cell sample (CD19+)

Relative Expression (log2-ratio):3.4831495
Number of Samples:3 / 2
Experimental B-CLL study 9 (CD19+; CD5+; untreated)
Untreated CD19+ CD5+ B-cell samples from subjects with chronic lymphocytic leukemia (CLL) and cultured in B-cell media. B-cells were isolated from peripheral blood mononuclear cells. Samples were collected from predominantly chemotherapy-naive patients representing the broad spectrum of CLL clinical heterogeneity, based on established prognostic risk factors (ZAP70 expression; degree of somatic hypermutation in the variable region of the immunoglobulin heavy chain [IGHV] gene; presence of specific CLL-associated cytogenetic abnormalities). All tumor samples were comprised of more then 95% tumor purity.
Control untreated normal B-cell sample (CD19+)
Untreated CD19+ B-cell samples from normal control subjects and cultured in B-cell media. B-cells were isolated from peripheral blood mononuclear cells.

T-cell activation study 2 / quiescent CD4+ T-cell sample

Relative Expression (log2-ratio):-3.4644184
Number of Samples:2 / 2
Experimental T-cell activation study 2
CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors were activated with plate bound CD3 (1ug/ml) and soluble CD28 (50ng/ml) for 2 days..
Control quiescent CD4+ T-cell sample
Quiescent CD4+ T-cell samples derived from PBMC´s of HIV-seronegative donors.

T-cell activation study 4 / normal resting T-cell sample

Relative Expression (log2-ratio):-3.4606647
Number of Samples:2 / 2
Experimental T-cell activation study 4
T-cell samples antiCD3 activated for 30hrs.
Control normal resting T-cell sample
T cells resting for 30h.